Clear answers about ketamine care.

Renue Wellness is a medically supervised mental health clinic offering advanced, evidence-based treatments for depression, PTSD, anxiety, OCD, and related conditions. Our team specializes in IV ketamine therapy, Spravato® (esketamine), and ketamine-assisted psychotherapy (KAP), delivered in calm, private suites by board-certified clinicians.

We currently operate clinics in New Hyde Park, NY (Long Island, Nassau County) and Paramus, NJ (Bergen County). A third location in Crestview, FL (Okaloosa County) is opening soon. Each suite is intentionally small and private so every visit feels unrushed.

We treat treatment-resistant depression, major depressive disorder, post-traumatic stress disorder (PTSD), generalized and social anxiety, obsessive-compulsive disorder (OCD), bipolar depression, postpartum depression, and suicidal ideation. We focus on patients for whom traditional medications and talk therapy alone have not provided enough relief.

No referral is required for IV ketamine or ketamine-assisted psychotherapy. Spravato® has specific FDA-defined clinical criteria, and our intake team will determine eligibility during your evaluation. You can request a consultation directly through our contact form.

Almost never. We work alongside your existing providers and, with your written permission, coordinate care so your therapist, prescriber, and primary doctor stay informed. Our goal is to add a new tool to your existing care team, not to replace it.

IV ketamine therapy is a medically supervised infusion of low-dose ketamine delivered through an intravenous line over about 40 minutes. At sub-anesthetic doses, ketamine acts on NMDA receptors and rapidly promotes synaptic plasticity, which is associated with relief from depression, PTSD, and chronic suicidal thoughts often within hours to days.

Many patients describe a meaningful shift in mood within 24 to 72 hours of their first or second infusion. Published studies on intravenous ketamine for treatment-resistant depression report response rates of roughly 50 to 70 percent across an induction series, with the most durable change usually arriving after the full series plus integration.

A standard induction series is six infusions over two to three weeks. After the series, many patients move to a maintenance schedule (one infusion every two to six weeks) that is tailored to how long their response holds. Your clinician will adjust dose, spacing, and total number of sessions based on your response.

When administered in a medical setting with proper screening and monitoring, low-dose ketamine has a strong safety record. Vital signs are monitored throughout the infusion, the dose is far below anesthetic levels, and our staff is trained in advanced cardiac and airway management. Common short-term effects include mild dissociation, blurry vision, nausea, and a transient rise in blood pressure, all of which resolve quickly after the infusion ends.

The most common side effects during treatment are dissociation (a floating or detached sensation), mild nausea, light-headedness, blurry vision, and a temporary increase in heart rate or blood pressure. These typically resolve within 30 to 60 minutes after the infusion. Persistent side effects are uncommon at therapeutic doses; long-term cognitive or bladder issues seen in recreational misuse are not associated with monitored medical use.

Yes. Therapeutic ketamine is not anesthesia. You remain awake, breathing on your own, and able to communicate with staff. Most patients describe a calm, dreamlike state. You will rest in a recliner with eye shades and music if you choose, and a clinician will be nearby throughout.

At the low, infrequent doses used in clinical care, ketamine has very low addictive potential. The medication is administered only at the clinic by trained staff and is never sent home. Patients with active substance use disorders are evaluated carefully before treatment to determine whether ketamine is appropriate.

Spravato® (esketamine) is an FDA-approved nasal spray for treatment-resistant depression and major depressive disorder with acute suicidal ideation. It contains the S-enantiomer of ketamine and is administered in a certified REMS clinic under direct medical observation. Compared to IV ketamine, Spravato® is FDA-approved on-label, often covered by insurance, and delivered as a nasal spray rather than an infusion.

Yes, Spravato® is frequently covered by commercial insurance plans, Medicare, and many Medicaid plans for patients who meet the FDA criteria for treatment-resistant depression. Our team will verify benefits, handle prior authorization, and give you a written cost estimate before your first dose.

After a brief vitals check, you self-administer the nasal spray under clinician supervision in a quiet, private suite. You are monitored for about two hours afterward to watch for sedation and blood pressure changes. You cannot drive after treatment, so plan for a ride or rideshare home.

The standard induction phase is twice weekly for four weeks, followed by once weekly for four weeks, then every one to two weeks for maintenance. Many patients continue maintenance dosing for several months to over a year, depending on response.

Common effects include dissociation, dizziness, sedation, nausea, mild blood pressure elevation, and a strange taste in the mouth. Effects usually resolve during the two-hour observation period. Because of these effects, Spravato® is only available through certified REMS clinics like ours.

Ketamine-assisted psychotherapy (KAP) combines low-dose ketamine with structured psychotherapy. A therapist prepares you in advance, sits with you during the medicine session to support the experience, and then guides integration sessions afterward to translate insights into lasting change.

Standard ketamine therapy focuses on the biological effects of the medication. KAP adds intentional psychotherapy on either side of the medicine session, which can be especially helpful for trauma, complex PTSD, grief, and existential distress where insight and processing matter as much as symptom relief.

Patients with PTSD, complex trauma, treatment-resistant depression, grief, end-of-life distress, or stuck patterns in long-term therapy often benefit most. You should be medically stable and willing to engage in talk therapy before and after the medicine session.

Medicine sessions usually run two to three hours, including settling in, the active medicine portion, and a recovery period. Preparation and integration sessions are typically 50 to 75 minutes each, scheduled in the days surrounding the medicine session.

IV ketamine and KAP are typically out-of-pocket because they are not FDA-approved on-label for psychiatric conditions. A typical IV infusion ranges from $450 to $700, and a KAP package ranges based on therapist time and number of sessions. Spravato® is usually covered by insurance. We provide a clear, written estimate before you commit.

Yes. We partner with healthcare financing providers such as CareCredit and Advance Care Card so you can spread treatment costs over time, often with 0 percent interest promotional periods. Our intake team will walk you through the options on your consultation call.

Yes. Most patients can use HSA and FSA funds for ketamine therapy and KAP. We provide itemized receipts with the appropriate medical codes for reimbursement and account documentation.

Plan for about 90 minutes total for an IV ketamine appointment (check-in, 40-minute infusion, and recovery), about two and a half hours for Spravato®, and two to three hours for a KAP medicine session. Initial evaluations are 60 to 90 minutes.

No. You may not drive for the remainder of the day after any ketamine or Spravato® session. Plan for a friend, family member, or rideshare to take you home. We are happy to help coordinate transportation.

Eat a light meal at least two hours before treatment, hydrate well, wear comfortable layered clothing, and arrange a ride home. Avoid alcohol and recreational substances for 24 hours before and after each session. Bring your ID and insurance card (for Spravato®).

Most psychiatric medications, including SSRIs, SNRIs, atypical antipsychotics, and mood stabilizers, are compatible with ketamine therapy. Benzodiazepines and lamotrigine can blunt the ketamine response and may need to be adjusted on the day of treatment. We coordinate any changes with your prescriber.